New Novartis data show early addition of twice-yearly* : vimarsana.com

V-INITIATE trial demonstrates that early initiation with Leqvio, prior to guideline-recommended ezetimibe, for ASCVD patients unable to achieve LDL-C goal...

Related Keywords

United States , South Korea , China , Switzerland , Netherlands , Amsterdam , Noord Holland , Japan , America , Swiss , Han , American , Jonathan Graham , Richard Jarvis , Isabella Zinck , Satoshi Sugimoto , Nicole Zinsli Somm , Coll Cardiol , Parag Mahanti , Michael Meo , Imke Kappes , Michael Koren , Marlena Abdinoor , Sloan Simpson , American Heart Association , Novartis Pharmaceuticals Corp , American College Of Cardiology Congress , Instagram , Alnylam Pharmaceuticals , European Society Of Cardiology Congress , World Health Organization , European Union , Jacksonville Center , Journal Of The American College Cardiology , Linkedin , Exchange Commission , European Medicines Agency , Facebook , World Heart Federation , American College Of Cardiology Heart Association , Clinical Research , Public Health , National Medical Products Administration , Novartis , Health Promotion Series , Annual Scientific Session , American College , Medical Director , Atherosclerotic Cardiovascular Disease , Cardiology Congress , European Society , Medical Products , Pharmaceuticals Corp , American Heart , American Heart Association Task Force , Clinical Practice , World Heart , Published May , Swiss Stock Exchange Novn , Ovartis Pharma Ag , Edia Release , Eimagine Medicine , Edical Innovations ,